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Purpose: The aim of this study was to evaluate the efficacy
of low-dose oral methotrexate (MTX) as a treatment for
patients with Kawasaki disease (KD) which was resistant to
intravenous immunoglobulin (IVIG). Patients and Methods:
The patients who had persistent or recrudescent fever after
treatment with IVIG were subsequently treated with low-dose
oral MTX [10mg/body surface area (BSA)] once weekly. Results:
Seventeen patients developed persistent or recrudescent fever
after treatment of KD with IVIG and were consequently given
MTX. The proportion of children with coronary artery lesions
(CALs) was 76%. The median value of maximum body
temperatures decreased significantly within 24 hours of MTX
therapy (38.6 vs. 37.0 , p < 0.001). The median CRP (C-
reactive protein) level was found to be significantly lower 1
week after administering the first dose of MTX (8.9 mg/dL vs.
1.2 mg/dL, p < 0.001). The median duration of fever before
MTX treatment was shorter in CALs (-) group than in CALs
(+) group (7 days vs. 10 days, p = 0.023). No adverse effects
of MTX were observed. Conclusion: MTX treatment for
IVIG-resistant KD resulted in quick resolution of fever and
rapid improvement of inflammation markers without causing
any adverse effects. MTX therapy should further be assessed
in a multicenter, placebo-blinded trial to evaluate whether it
also improves coronary artery outcome.
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INTRODUCTION
Kawasaki disease is an acute febrile, systemic
vasculitic syndrome of unknown etiology, occurring
primarily in children younger than 5 years of age.
In 15% to 25% of children with untreated KD,
coronary artery aneurysms or ectasia develop,
which can lead to myocardial infarction, sudden
death, or ischemic heart disease. The standard
care for children with acute KD includes with
high-dose intravenous immunoglobulin and
aspirin.
1,2 In 10% to 15% of KD patients, high-dose
IVIG fails to initiate defervescence.
3,4 Although the
majority of children who have incomplete responses
to an initial dose of IVIG experience improvement
in their condition with additional IVIG; some
appear to have diseases refractory to this mode of
therapy. However, coronary artery dilatation
continues to progress in these patients. Corticos-
teroids have been used to treat KD patients with
recrudescent or persistent fever even after IVIG
treatment. Several studies have shown that
corticosteroids improve symptoms with no severe
adverse events.
5,6 However, the effects of steroids
on coronary artery abnormalities are still uncer-
tain.
We were impressed with several severe cases of
KD that were unresponsive to repeated doses of
IVIG and required 1 or 2 doses of MTX to sup-
press the inflammatory response.
7,8 We, therefore,
investigated the effects of MTX on clinical
symptoms, laboratory indices, and the progression
of coronary artery dilatations in patients with
IVIG-resistant KD. Also, we compared demo-
graphic characteristics and laboratory findings
between coronary artery lesions (+) and (-)
groups.
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PATIENTS AND METHODS
Study subjects
Study subjects were patients with KD who were
treated at Severance Children's Hospital, Korea,
between August 2001 and July 2006. All patients
fulfilled at least 5 of the 6 criteria for diagnosing
KD. All patients were initially given high-dose
IVIG (2 g/kg) and aspirin (100 mg/kg) within the
first 10 days of fever onset. The patients were
considered IVIG-resistant when fever ( 37.5 ,
axillary temperature) persisted or recurred 48
hours after treatment with high-dose IVIG and
aspirin.
MTX treatment
The patients with IVIG-resistant KD were sub-
sequently treated with low-dose oral MTX [10
mg/body surface area (BSA)] once weekly without
folate supplementation. Administration of MTX
was continued in all subjects until C-reactive
protein (CRP) levels were normalized. Exclusion
criteria included previous use of glucocorticoids,
diagnosis of chronic liver disease, and presence of
renal insufficiency. Day 1 was defined as the first
day of administration of MTX. Written informed
consent was obtained from the parents of children
included in this study.
Laboratory tests were performed on all subjects
before administration of MTX and once every
week during hospitalization. Laboratory evalua-
tion included white blood cell count, hematocrit,
platelet count, aspartate aminotransferase, albumin,
erythrocyte sedimentation rate, and CRP.
Harada's score was assessed within 24 hours
before the start of MTX treatment.
9 No patients
were given any exogenous supplementation of
albumin. Echocardiograms were performed weekly
during hospitalization and 1 month after dis-
charge. CALs were defined according to the
criteria of the Japanese Ministry of Health.
10
Statistical analysis
The Wilcoxon rank-sum tests were used to
compare variables with non-normal distributions.
Categorical data was assessed using a 
2 test with
the Fisher exact test. All reported p values are
two-sided, and p values of less than 0.05 were
considered statistically significant.
RESULTS
Subjects characteristics
There were 17 KD patients who were sub-
sequently treated with MTX when they had
persistent or recrudescent fever after IVIG
administration. Age at disease onset ranged from
4 months to 8 years (median, 2.7 years). The
median duration of fever before initiating IVIG or
MTX therapy was 4 days and 9 days, respectively.
Of these, 13 patients (76%) had CALs, consisting
of 2 patients (12%) with giant aneurysms ( 8
mm), 3 patients (18%) with small aneurysms, and
8 patients (47%) with a transient dilatation during
treatment. The 2 patients with giant aneurysms
were either younger than 6 months or older than
6 years.
MTX treatment
The median value of maximum body tempera-
tures decreased significantly within 24 hours of
initiating MTX treatment (38.6 vs. 37.0 , p <
0.001) (Fig. 1). After giving the first dose of MTX,
3 patients had recrudescent fever on day 7, while
1 patient had fever on day 14. However, all 4
patients with recrudescent fever were responsive
to the second or third dose of MTX within 24
hours of administration. The median CRP level
decreased significantly 1 week after administra-
tion of the first dose of MTX (8.9 mg/dL vs. 1.2
mg/dL, p < 0.001) (Fig. 2). MTX was discontinued
with no recurrence of fever in all 17 patients. The
median cumulative dose of MTX was 20 mg/BSA
(range, 10 - 50). No adverse effects of MTX were
observed.
Comparison between CALs (-) and (+) groups
There was no difference in the demographic
characteristics and laboratory findings before
MTX therapy between CALs (-) and (+) groups
(Table 1). The median duration of fever beforeTable 1. Comparison of Demographic Characteristics and Laboratory Findings before MTX Therapy between
CALs (-) and (+) Groups*
Characteristic CALs (-) (n = 4) CALs (+) (n = 13) p value
Age (yrs)
< 6 mo or > 6 yr (%)
3.5 (1.6 - 4.9)
0
2.4 (1.4 - 5.8)
31
0.956
0.519
Males (%) 50 46 1.000
WBC count (10
6/L) 14,765 (8,603 - 18,528) 15,940 (11,775 - 23,095) 0.549
Hematocrit (%) 31.4 (30.3 - 32.9) 29.4 (28.0 - 32.1) 0.130
Platelet count (10
9/L) 509 (384 - 687) 370 (289 - 776) 0.624
CRP (mg/dL) 3.6 (2.1 - 10.3) 9.6 (4.9 - 16.0) 0.163
ESR (mm/hr) 63 (40 - 120) 93 (48 - 120) 0.659
AST (IU/L) 36 (27 - 46) 33 (23 - 53) 0.956
Albumin (g/dL) 3.8 (3.1 - 4.3) 3.0 (2.5 - 3.8) 0.130
Harada's score 3 (3 - 4) 4 (3 - 5) 0.267
Duration of fever before initial IVIG (days) 4.5 (3.3 - 5.8) 3.0 (3.0 - 5.5) 0.624
Total dose of IVIG (g/kg) 3 (2 - 4) 4 (4 - 7) 0.102
Duration of fever before starting MTX (days) 7 (7 - 7) 10 (8 - 12) 0.023
Cumulative dose of MTX (mg/BSA) 10 (10 - 10) 20 (10 - 35) 0.074
AST, aspartate aminotransferase; BSA, body surface area; CALs, coronary artery lesions; CRP, C-reactive protein; ESR,
erythrocyte sedimentation rate; IVIG, intravenous immunoglobulin; MTX, methotrexate; WBC, white blood cell.
*Expressed as median (interquartile range) or percent.
Harada's score is a risk score of cardiac complications, commonly used in Japan.
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Fig. 1. Changes in the maximum body temperature
attained each day after treatment with MTX. The starting
day of MTX was defined as day 1. The upper and lower
ends of each box indicate the first and third quartiles, and
the line inside the box represents the median value. The
upper fence of a whisker corresponds with the largest
value within 1.5 times the interquartile range above the
third quartile and the lower fence of a whisker is the
smallest value within 1.5 times the interquartile below the
first quartile. Values beyond the fences are marked with
circles. MTX, methotrexate. *p < 0.001.
Fig. 2. Changes in the serum level of CRP after treatment
with MTX. Compared with the pretreatment phase, the
reduction in serum levels of CRP on day 7 was
significantly greater with MTX administration (p < 0.001).
The upper and lower ends of a box show the first and
third quartiles, and the line inside the box the median
value. The upper fence of a whisker represents the largest
value within 1.5 times the interquartile range above the
third quartile and the lower fence of a whisker the
smallest value within 1.5 times the interquartile below the
first quartile. Values beyond the fences are marked with
circles. CRP, C-reactive protein; MTX, methotrexate.Low-dose MTX Therapy for IVIG-resistant KD
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starting MTX was shorter in CALs (-) group than
in CALs (+) group (7 days vs. 10 days, p = 0.023).
DISCUSSION
MTX (4-aminno-N10-methylpteroyl glutamic
acid) is an analogue of folic acid and functions as
a folic acid antagonist like aminopterin. Since
1948, when Farber et al. first described clinical
remissions in children with acute leukemia after
treatment with aminopterin, MTX has been used
to treat millions of patients with malignant and
autoimmune diseases. It is estimated that at least
500,000 patients worldwide with rheumatoid
arthritis have prescribed MTX, making it by far
the most commonly used disease-modifying
anti-rheumatic drug. MTX has been found to be
safe and well tolerated with its current usage at
low-doses.
Many pharmacological mechanisms of MTX
action have been proposed, including inhibition of
purine biosynthesis, promotion of adenosine
release, inhibited production of proinflammatory
cytokines, suppression of lymphocyte prolifera-
tion, neutrophil chemotaxis and adherence, and
reduction of serum immunoglobulin. However,
the mechanism by which MTX at a low dose
modulates inflammation is still unknown. Studies
to date indicate that the most important actions of
low-dose MTX are its effects on increasing
adenosine level and reducing the pro-inflamma-
tory while simultaneously increasing the anti-
inflammatory cytokine levels. Higher levels of
cyclic adenosine monophosphate (cAMP) produce
a range of anti-inflammatory effects, which include
decreased secretion of tumor necrosis factor
(TNF), interferon (IFN)- , interleukin (IL)-12, IL-6, γ
and inhibition of phagocytosis.
11,12 Thus, adenosine-
mediated anti-inflammatory effects may play a
central role in producing the anti-inflammatory
actions of MTX.
13 Striking immune perturbations
occur in acute KD, including marked cytokine
cascade stimulation and endothelial cell activation.
Concentrations of many proinflammatory cyto-
kines and chemokines, including TNF , INF- , α γ
IL-1, IL-6, and IL-8, are higher than normal during
the acute phase of the disease.
14,15 The involvement
of such an inflammatory process in KD led us to
consider the use of MTX in the treatment of KD.
In this study, MTX treatment resulted in rapid
defervescence and improvement of acute-phase
reactants in all patients with IVIG-resistant KD.
No patient had recurrent fever after cessation of
MTX therapy. In all trials with MTX, the drug was
found to be generally well tolerated, but with
some toxicity; most commonly gastrointestinal,
stomatitis, alopecia, marrow suppression, and
liver function abnormalities. However, the median
cumulative dose of MTX was so low that no
adverse effects were observed. Aspirin appeared
to decrease total clearance and renal clearance of
MTX while concurrently increasing the area under
the concentration-time curve (AUC) of MTX. The
pharmacokinetic interaction between aspirin and
MTX is greater than that of most other non-
steroidal anti-inflammatory drugs, but this
interaction is of little clinical significance.
16
Current alternative treatments available after
response failure to initial IVIG therapy are unsa-
tisfactory because they cannot quickly attenuate
systemic inflammation. A persistent, systemic
inflammatory state results in a remarkably higher
incidence of coronary artery involvement, as seen
with IVIG-resistant patients, when compared with
IVIG-responsive patients.
17 These findings suggest
that earlier and more effective primary therapy is
required for refractory KD. More aggressive
primary treatment with adjuvant MTX might
benefit children who are determined to be at high
risk for IVIG-resistance at baseline. As very few
options are available to clinicians after IVIG and
aspirin fail to lower the temperature and CRP in
acute KD patients, any drug that can prevent
long-term sequelae such as coronary artery
aneurysms should be credited and investigated in
further similar trials. The small sample size in this
single-center study provided insufficient power
for the assessment of coronary artery outcome and
adverse events. The most severe limitation of this
study was the lack of a placebo group.
In summary, our patients treated with MTX
experienced fast resolution of fever and rapid
improvement of inflammation markers without
causing adverse effects. MTX therapy should
further be assessed in a multicenter, placebo-
blinded trial to determine whether it improves
coronary artery outcome.Taek Jin Lee, et al.
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